Wed, Jul 30, 2014, 11:46 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Albany Molecular Research Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • agoodlaughtoday agoodlaughtoday Mar 24, 2012 10:42 AM Flag

    Close the Doors

    That's too simplistic of an analysis. What you have is a management team, which purchased at what they perceived as a steal underperforming assets, which in reality they overpaid for. Coupled with the arrogance that it wasn't their fault that they didn't understand the pharmaceutical market was reducing R&D expenditures which in my opinion, the management teams of the companies that sold AMRI the underperforming sites understood and cleverly conveyed the opposite to AMRI's senior management team.
    If it wasn't for the Rensselaer cash cow the underperformance of the acquired sites, i.e., Massachusetts, UK and Hungary would be glaringly apparent. If this failure of adequately performing due diligence had been conducted by a junior member of AMRI management team the pro-AMRI senior management employees who post on this board would have already lamented the fact.
    When you watch a management team in action sometimes, what they don't discuss in press releases is as important as what they do. An example there has been no press releases about new revenue opportunities emerging from the acquired UK and Massachusetts site's

    SortNewest  |  Oldest  |  Most Replied Expand all replies
19.37+0.01(+0.05%)Jul 30 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.